Shahzad Hashmi, MD
Psychiatry · Gainesville, GANPI 1770566341
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 32.7% of the total. Reporting peaked in 2023 at $21,708 and has fallen 58.7% since, to $8,974 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,138 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$23K
- Supernus Pharmaceuticals, Inc.$9K
- Alkermes, Inc.$8K
- Indivior Inc.$7K
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$3K
- plus $17K from 31 others
Across 207 payments — averaging $2909.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$43K
- Alkermes, Inc.$30K
What the payments were for
- Consulting fees$5,1007%
- Speaking & faculty fees$26,99939%
- Travel & lodging$3,2555%
- Food & beverage$33,83848%
- Education$6091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$19,918
- REXULTI$19,193
- QELBREE$6,515
- PERSERIS$4,777
- Auvelity$1,000
- ARISTADA$456
- VRAYLAR$244
- NUEDEXTA$209
- ABILIFY MAINTENA$115
- ABILIFY ASIMTUFII$115
- ARISTADA INITIO$114
- Austedo XR$114
- INVEGA SUSTENNA$110
- AUSTEDO$107
- INGREZZA$102
- CAPLYTA$102
How this compares
$69,802 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 153 | $1,062,662 |
| IngrezzaValbenazine Tosylate | 79 | $653,512 |
| LybalviOlanzapine/Samidorphan Malate | 364 | $587,708 |
| AustedoDeutetrabenazine | 40 | $423,316 |
| AristadaAripiprazole Lauroxil | 122 | $348,209 |
| RexultiBrexpiprazole | 194 | $305,301 |
| Invega SustennaPaliperidone Palmitate | 95 | $251,510 |
| PerserisRisperidone | 82 | $214,488 |
| CaplytaLumateperone Tosylate | 126 | $212,615 |
| FanaptIloperidone | 87 | $206,796 |
| Invega TrinzaPaliperidone Palmitate | 23 | $176,770 |
| UzedyRisperidone | 57 | $162,009 |
| AplenzinBupropion Hbr | 35 | $140,662 |
| VraylarCariprazine Hcl | 91 | $124,492 |
| AuvelityDextromethorphan Hbr/Bupropion | 124 | $117,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $3,327 | $1,647,987250 claims |
| Alkermes, Inc.Lybalvi, Aristada | $7,931 | $935,917486 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,314 | $653,51279 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato | $1,046 | $509,095158 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $22,855 | $419,512237 claims |
| Indivior Inc.Perseris | $6,601 | $214,48882 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,123 | $212,615126 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,787 | $206,79687 claims |
| Bausch Health US, LLCAplenzin | $916 | $140,66235 claims |
| AbbVieVraylar | $2,997 | $124,49291 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,433 | $117,166124 claims |
| Eisai Inc.Fycompa | $211 | $108,39383 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Gainesville
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.